Please assess the completion status of the following clinical trial:

Trial Title: Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First diagnosis of coronary heart disease and received a PCI treatment.~* Age 18-65 years.~* Able and willing to provide written informed consent.~Exclusion Criteria:~* Speech communication barriers.~* Patients with a clear history of allergies to anti-platelet drugs.~* Patients with a clear history of allergies to anti-platelet ᵦ-blockers.~* Patients with a clear history of allergies to statin drugs.~* Patients with a clear history of allergies to antihypertensive drugs.~* Patients with a clear history of allergies to antidiabetic drugs.~* Patients with serious heart failure(better than NYHA class II).~* Patients with cerebral infarction or cerebral hemorrhage.~* Patients with liver dysfunction (AST and ALT\> 2 times that of the reference value).~* Patients with kidney dysfunction (creatinine clearance rate\< 60ml/min).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Smart phone app (Type: EXPERIMENTAL): The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
- Control group (Type: OTHER): Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).